Search
Atezolizumab per al tractament del carcinoma urotelial localment avançat o metastàtic
(2018-10-18)
Urothelial carcinoma (CU) of urinary tract, also known as cell carcinoma transitional of the urinary tract, represents around 85-95% of all the cancers of the urinary tract. The term urothelial refers to the epithelium ...
Edoxaban: prevenció de l'ictus i de l'embòlia sistèmica en pacients adults amb fibril.lació auricular no valvular amb almenys un factor de risc
(2017-02)
Edoxaban is the third direct inhibitor of factor X marketed in Spain. In the main clinical trial, it has shown similar efficacy in the prevention of stroke or systemic embolism and a reduction in serious haemorrhages ...
Dolor lumbar 2018 (37/2020)
(2020-01)
Back pain (cervical, dorsal or lumbar) is a health problem that affects a significant proportion of the population and generates a high demand for services throughout the CatSalut healthcare network. According to the 2018 ...
Burosumab per al tractament de la hipofosfatèmia congènita
(2021-01-21)
X-linked hypophosphatemia (HLX) is a dominant, chronic, and debilitating inherited disease caused by inactivating mutations in the PHEX gene (Phosphate-regulating gene with homologies to endopeptidases on the X chromosome). ...
Pertuzumab en combinació amb trastuzumab i quimioteràpia per al tractament neoadjuvant de pacients adults amb càncer de mama HER2 positiu, localment avançat, inflamatori, o en estadi precoç amb alt risc de recaiguda: informe d'avaluació de resultats
(2020)
Breast cancer (BC) is the most common neoplasm in women and the leading cause of cancer death in European women. Pertuzumab is a monoclonal antibody that inhibits epidermal growth factor (HER2) receptor 2 dimerization. The ...
Tezacaftor/ivacaftor (Symkevi®) per al tractament de la fibrosi quística
(2019-10-15)
Cystic fibrosis (CF) is an autosomal recessive disorder caused by mutations in the gene that encodes the transmembrane conductance regulator of CF (CFTR), a protein that acts as a chloride channel. Viscous secretions ...
Propiverina per al tractament dels símptomes urinaris en la síndrome de bufeta hiperactiva
(2018-09-26)
Hyperactive bladder syndrome (SBH) is characterized by urinary urge, with urinary incontinence (UU) of urgency or without, with absence of infection or of another obvious pathology, and that is usually associated with an ...